The Unique Characteristics of MET Exon 14 Mutation in Chinese Patients with NSCLC

Si‐Yang Maggie Liu(University of Arizona), Yi‐Long Wu(Guangdong Academy of Medical Sciences)

Journal of Thoracic Oncology

May 30, 2016

10.1016/j.jtho.2016.05.016

Cited by 67

Related Papers

Gefitinib or Carboplatin–Paclitaxel in Pulmonary Adenocarcinoma

|New England Journal of Medicine|2009|8.2k

Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study

|The Lancet Oncology|2011|4.1k

Crizotinib versus Chemotherapy in Advanced <i>ALK</i> -Positive Lung Cancer

|New England Journal of Medicine|2013|3.4k

Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial

|The Lancet|2019|3.4k

Osimertinib or Platinum–Pemetrexed in <i>EGFR</i> T790M–Positive Lung Cancer

|New England Journal of Medicine|2016|3.3k